MARKET

IMUX

IMUX

Immunic Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.15
-0.27
-2.87%
Opening 14:06 09/20 EDT
OPEN
9.28
PREV CLOSE
9.42
HIGH
9.74
LOW
9.05
VOLUME
64.91K
TURNOVER
--
52 WEEK HIGH
28.21
52 WEEK LOW
7.69
MARKET CAP
240.18M
P/E (TTM)
-2.4765
1D
5D
1M
3M
1Y
5Y
Immunic, Inc. to Participate in Investor and Scientific Conferences in September
/PRNewswire/ -- a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific...
PR Newswire - PRF · 09/08 10:30
HC Wainwright & Co. Maintains Buy on Immunic, Lowers Price Target to $25
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $40 to $25.
Benzinga · 09/07 10:21
HC Wainwright Adjusts Immunic's Price Target to $25 from $40, Keeps Buy Rating
MT Newswires · 09/07 09:21
Otter Creek Advisors, LLC Buys Avantor Inc, Clarivate PLC, BRP Group Inc, Sells Hilton ...
GuruFocus News · 08/13 19:38
Here's Why We're Watching Immunic's (NASDAQ:IMUX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 08/11 08:53
12 Health Care Stocks Moving In Friday's Intraday Session
 
Benzinga · 08/06 16:36
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5)
Benzinga · 08/06 11:42
Immunic EPS misses by $0.15
Immunic (NASDAQ:IMUX): Q2 GAAP EPS of -$0.82 misses by $0.15. Cash and Cash Equivalents as of June 30, 2021, were $87.2M, which does not include the approximately $42.2M raised in
Seekingalpha · 08/06 10:39
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMUX. Analyze the recent business situations of Immunic Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMUX stock price target is 54.50 with a high estimate of 71.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 80
Institutional Holdings: 9.60M
% Owned: 36.57%
Shares Outstanding: 26.25M
TypeInstitutionsShares
Increased
30
970.25K
New
6
54.59K
Decreased
10
92.01K
Sold Out
8
798.19K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.34%
Pharmaceuticals & Medical Research
-1.20%
Key Executives
Chairman/Executive Director
Duane Nash
President/Chief Executive Officer/Director
Daniel Vitt
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance
Glenn Whaley
Chief Operating Officer
Manfred Groppel
Chief Scientific Officer
Hella Kohlhof
General Counsel
Inderpal Singh
Other
Andreas Muehler
Independent Director
Tamar Howson
Independent Director
Jorg Neermann
Independent Director
Vincent Ossipow
Independent Director
Barclay Phillips
Independent Director
Jan Van den Bossche
No Data
  • All
  • Financials
  • Insiders
More
About IMUX
Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.

Webull offers kinds of Immunic Inc stock information, including NASDAQ:IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.